Analyst Reco. Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:59:24 18/06/2025 BST			5-day change	1st Jan Change
34.88 ^USD	+0.52%		-7.33%	+7.19%

06-16	SPIC Yuanda Environmental Protection Names Chief Accountant	MT
06-05	Legend Biotech Corporation Appoints Peter Salovey as Lead Independent Director, Effective June 5, 2025	CI

Analyst Reco.

Truist Securities Adjusts Legend Biotech Price Target to $71 From $88, Maintains Buy Rating	05-14	MT
RBC Trims Price Target on Legend Biotech to $84 From $86, Keeps Outperform Rating	01-07	MT
UBS Lowers Legend Biotech Price Target to $65 From $75, Maintains Buy Rating	12-09	MT
Redburn Initiates Legend Biotech at Buy With $86 Price Target	08/10/24	MT
TD Cowen Adjusts Legend Biotech Price Target to $67 From $71, Maintains Buy Rating	15/07/24	MT
Truist Securities Initiates Legend Biotech With Buy Rating, $88 Price Target	17/06/24	MT
HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating	24/05/24	MT
Deutsche Bank Starts Legend Biotech With Buy Rating	24/05/24	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating	14/05/24	MT
RBC Adjusts Price Target on Legend Biotech to $86 From $85 on Model Updates, Maintains Outperform Rating	14/05/24	MT
Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65	17/04/24	MT
Cantor Fitzgerald Initiates Legend Biotech With Overweight Rating	03/04/24	MT
UBS Adjusts Legend Biotech Price Target to $81 From $76, Maintains Buy Rating	18/03/24	MT
Raymond James Starts Legend Biotech With Outperform Rating, $86 Price Target	13/03/24	MT
RBC Trims Price Target on Legend Biotech to $85 From $86, Keeps Outperform Rating	03/01/24	MT
Scotiabank Initiates Legend Biotech With Sector Perform Rating, $65 Price Target	19/12/23	MT
HC Wainwright Raises Price Target on Legend Biotech to $87 From $86, Keeps Buy Rating	15/11/23	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $85, Keeps Buy Rating	18/10/23	MT
Barclays Adjusts Price Target on Legend Biotech to $93 From $92, Maintains Overweight Rating	18/10/23	MT
Barclays Adjusts Price Target on Legend Biotech to $92 From $90, Maintains Overweight Rating	21/07/23	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $85 From $82, Maintains Buy Rating	21/07/23	MT
Morgan Stanley Raises Price Target on Legend Biotech to $85 From $65, Maintains Overweight Rating	20/07/23	MT
BTIG Raises Price Target on Legend Biotech to $90 From $85, Maintains Buy Rating	13/06/23	MT
HC Wainwright Adjusts Legend Biotech Price Target to $82 From $77, Maintains Buy Rating	06/06/23	MT
William Blair Initiates Legend Biotech at Market Perform	25/05/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Analyst Reco.

Filters